Quality of life in hypertensive patients treated by prazosin (sustained release)or enalapril: a randomized double blind trial over 24 weeks

摘要

The importance of the criterion of Quality of Life(QOL) for compliance with antihypretensive drugs led us to study the QOL of 51 hypertensives receiving 2.5 mg of the new formulation of prazosin(sustained release), compared with 49 subjects treated by a converting enzyme inhibitor(enalapril 10 mg), in a double-blind randomized trial. QOL, assessed by means of a 22 item self- administered questionnaire, improved significantly with prazosin, during the 24 weeks of the trial.